BWM
ABBV icon

Baystate Wealth Management’s AbbVie ABBV Stock Holding History

Baystate Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$777K Buy
5,011
+714
+17% +$104K 0.06% 109
2023
Q3 		$641K Buy
4,297
+225
+6% +$33K 0.05% 113
2023
Q2 		$549K Sell
4,072
-280
-6% -$41.1K 0.05% 126
2023
Q1 		$694K Buy
4,352
+133
+3% +$20.3K 0.06% 110
2022
Q4 		$682K Sell
4,219
-80
-2% -$12.3K 0.06% 121
2022
Q3 		$577K Buy
4,299
+35
+0.8% +$5.02K 0.06% 111
2022
Q2 		$653K Sell
4,264
-68
-2% -$10.4K 0.06% 101
2022
Q1 		$702K Sell
4,332
-67
-2% -$9.73K 0.06% 97
2021
Q4 		$596K Buy
4,399
+399
+10% +$47.1K 0.05% 105
2021
Q3 		$432K Buy
4,000
+287
+8% +$32.8K 0.04% 104
2021
Q2 		$418K Buy
3,713
+198
+6% +$22.3K 0.04% 105
2021
Q1 		$380K Buy
3,515
+31
+0.9% +$3.32K 0.04% 104
2020
Q4 		$373K Sell
3,484
-1,471
-30% -$141K 0.04% 93
2020
Q3 		$434K Buy
4,955
+266
+6% +$25K 0.05% 82
2020
Q2 		$460K Buy
4,689
+422
+10% +$37.2K 0.05% 78
2020
Q1 		$325K Buy
4,267
+25
+0.6% +$2.13K 0.04% 80
2019
Q4 		$376K Buy
4,242
+881
+26% +$73.1K 0.05% 76
2019
Q3 		$254K Sell
3,361
-718
-18% -$49.2K 0.03% 96
2019
Q2 		$299K Buy
4,079
+28
+0.7% +$2.2K 0.04% 88
2019
Q1 		$319K Sell
4,051
-208
-5% -$17K 0.04% 86
2018
Q4 		$381K Buy
4,259
+27
+0.6% +$2.37K 0.06% 69
2018
Q3 		$394K Buy
4,232
+410
+11% +$38.9K 0.07% 59
2018
Q2 		$363K Buy
3,822
+20
+0.5% +$1.95K 0.05% 60
2018
Q1 		$354K Hold
3,802
– – 0.05% 56
2017
Q4 		$405K Hold
3,802
– – 0.06% 58
2017
Q3 		$345K Sell
3,802
-227
-6% -$17.3K 0.06% 57
2017
Q2 		$293K Sell
4,029
-1,109
-22% -$74.6K 0.05% 58
2017
Q1 		$331K Buy
5,138
+1,796
+54% +$113K 0.06% 54
2016
Q4 		$212K Buy
+3,342
New +$204K 0.04% 59
2013
Q3 		– Sell
-740
Closed -$31K – 28
2013
Q2 		$31K Buy
+740
New +$32.4K 0.02% 122

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Baystate Wealth Management's ABBV Position: Q4 2023 in Review

Baystate Wealth Management increased its AbbVie (ABBV) stake by 17% in Q4 2023, buying an estimated $104K and bringing the position to 5,011 shares worth $777K. The position accounts for 0.06% of the portfolio, ranked #109.

Baystate Wealth Management first reported a position in ABBV in Q2 2013 and has held it in 30 quarters since. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

  • Baystate Wealth Management held 5,011 shares of AbbVie worth $777K as of Q4 2023.
  • Baystate Wealth Management bought 714 AbbVie shares in Q4 2023, an estimated $104K.
  • AbbVie made up 0.06% of Baystate Wealth Management's portfolio in Q4 2023, its #109 holding.
  • Baystate Wealth Management first reported a position in AbbVie in Q2 2013 and has held it in 30 quarters since.
  • 3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.